Shilpa Medicare has been granted a patent for a process to prepare highly pure crystalline Bortezomib, a medication used in cancer treatment. The patent covers a specific crystalline form, SB-I, with distinct peaks and thermal properties. GlobalData’s report on Shilpa Medicare gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Shilpa Medicare, Nanoparticle drug conjugates was a key innovation area identified from patents. Shilpa Medicare's grant share as of April 2024 was 20%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for crystalline form of bortezomib
A recent patent (Publication Number: US11964993B2) has been granted for a crystalline form of bortezomib, known as crystalline form SB-I. This form is characterized by specific peaks at 6.00, 12.07, 13.25, 18.72, 18.88, 19.13, 21.46, 23.66, 24.07, 24.46, and 25.97±0.2°, as well as an endothermic peak in the DSC isotherm between 101 to 103°C. Additionally, the crystalline form SB-I has a water content ranging from 8 to 10% w/w based on the Loss on Drying method using thermo gravimetric analysis (TGA).
This patented crystalline form of bortezomib offers a unique and specific molecular structure that distinguishes it from other forms of the drug. The defined peaks and thermal characteristics outlined in the claims provide a clear identification of the crystalline form SB-I, making it a valuable addition to the field of pharmaceutical research and development. The precise water content range further contributes to the understanding and potential applications of this form of bortezomib in various medical contexts.
To know more about GlobalData’s detailed insights on Shilpa Medicare, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
